Τα πιστοποιητικά είναι διαθέσιμα!
Registration
Welcome address A. Klinakis (GR)
Chairs: V. Georgoulias (GR), A. Klinakis (GR)
Precision Medicine and the “Genome Greece” D. Thanos (GR)
Chairs: Th. Rampias (GR), Z. Lygerou (GR)
09.45-10.05: Mechanisms for DNA damage repair (DDR) D. Karagiannis (GR)
10.05-10.25: Stress-induced senescence and role in tumor growth A. Goutas (GR)
10.25-10.35: Discussion
Coffee Break
Chairs: S. Linardopoulos (UK), F. Papageorgiou (GR)
11.00-11.20: Molecular basis of HR Deficiency and Synthetic lethality A. Klinakis (GR)
11.20-11.40: Genomic signatures of HRD in cancer genome
(In silico, mut signatures e.t.c) P. Constantoulakis (GR)
11.40-12.00: PARP inhibitor technology, parylation T. Rampias (GR)
12.00-12.10: Discussion
Chairs: A. Klinakis (GR), Th. Rampias (GR)
12.10-12.40: PETRA: First-in-human Phase 1/2a trial of the first-in-class
new generation PARP1 inhibitor saruparib in patients with
advances solid tumours with BRCA1/2, PALB2 or
RAD51C/D mutations S. Linardopoulos (UK)
12.40-13.10: Understanding and targeting PARP inhibitor resistance S. Pettitt (UK)
13.10-13.40: Shieldin Loss and PARP Inhibitor Resistance:
Unravelling Mechanisms in Cancer Cells W. Niedzwiedz (UK)
13.40-13.50: Discussion
Light Lunch
Chair: P. Constantoulakis (GR), F. Papageorgiou (GR)
14.30-14.50: Evaluation of NGS testing modalities for
HRD scoring G. Christopoulou (GR)
14.50-15.10: Non-NGS-based assessment for of HRD E. Papadopoulou (GR)
15.10-15.20: Discussion
Chairs: Th. Rampias (GR), W. Niedzwiedz (UK)
Role of Timeless and PARP1 in Transcription-Replication Collisions Th. Halazonetis (CH)
Discussion
Chairs: K. Baxevanis (GR), V. Anastasopoulou (GR)
09.00-09.20: Tumor microenvironment and immunogenicity I. Pateras (GR)
09.20-09.40: The heterogeneous molecular landscape of NSCLC N. Karachaliou (DE)
09.40-10.00: HRD and tumor immunogenicity P. Verginis (GR)
10.00-10.10: Discussion
Chairs: A. Klinakis (GR), V. Georgoulias (GR)
The Chronic Stress and Inflammation Syndrome and Cancer G. Chrousos (GR)
Coffee Break
Chairs: V. Georgoulias (GR), S. Pettitt (UK)
11.00-11.20: Revealing the HRD status in NSCLC K. Tsiligiri (GR)
11.20-11.40: CSMD1 deletions in HRD cluster of HNSCC T. Rampias (GR)
11.40-12.00: Concordance between HRD Assays in Patients with
High-Grade Epithelial Ovarian Cancer E. Fountzila (GR)
12.00-12.20: Epigenetics and HRD A. Klinakis (GR)
12.20-12.30: Discussion
Chairs: S. Linardopoulos (UK), V. Georgoulias (GR)
12.30-12.50: Targeting POLθ in BRCA-deficiency J. Loizou (UK)
12.50-13.10: ASCO 2024: Update of treatment for
HRD tumors A. Constantinidou (CY)
13.10-13.30: Combination of PARP inhibition with
immunotherapy V. Anastasopoulou (GR)
13.30-13.50: Combination of PARP inhibitors with other treatments O. Fiste (GR)
13.50-14.00: Discussion
Concluding Remarks
